In breast cancer, where NIS is often expressed endogenously, the radioablative effects of NIS-mediated 131I− accumulation could conceivably be enhanced by combining 131I− with an anticancer agent that increases tumor cell vulnerability to the DNA-damaging effects of radiation. The gene discussed is SLC5A5; the disease is breast cancer.